Naysmith T E, Blake D A, Harvey V J, Johnson N P
fertilityPLUS, National Women's Hospital, Auckland, New Zealand.
Hum Reprod. 1998 Nov;13(11):3250-5. doi: 10.1093/humrep/13.11.3250.
This study was designed to assess the effect of cancer treatments on the natural and assisted reproductive potential of men. A cohort of men with cancer, in whom radiotherapy and/or chemotherapy was planned, were invited to participate. Twenty-two pre- and post-treatment semen samples were analysed. The reproductive potential of participants was assessed with respect to the current range of fertility treatment options available. Abnormal sperm concentrations were found in 27% of patients pre-treatment compared to 68% post-treatment following a mean latency of 20 months from treatment. Fifty-nine percent of patients experienced a clinically significant decrease in sperm, concentration following radiotherapy and/or chemotherapy; 23% developed azoospermia following treatment. Eighty-two percent of patients with testicular malignancy had oligo- or azoospermia post-treatment. Only one patient had a clinically significant reduction in the percentage of motile spermatozoa post-treatment. Cryopreservation of semen prior to treatment improved the fertility prospects of 55% of patients. Intracytoplasmic sperm injection (ICSI) enhanced the fertility prospects of a further 14%. In the absence of, or after depletion of, cryopreserved semen, ICSI could enhance the fertility prospects of 45% of patients. Fertilization has been achieved by ICSI using spermatozoa retrieved by testicular biopsy from an azoospermic testicular cancer survivor 8 years after chemotherapy. It was concluded that chemotherapy and/or radiotherapy may depress semen concentration to the extent of rendering a man infertile. The severity of the reduction in sperm concentration following treatment is unpredictable but likely to be most severe in those with testicular malignancy and those treated with radiotherapy or alkylating chemotherapy agents. Not all men are keen to undergo an appraisal of their post-treatment fertility potential, for reasons which are unclear. Improving awareness and education of patients concerning the effects of both cancer and cancer treatments on reproductive potential is essential. With the advent of ICSI, it is possible to offer a very reasonable chance of conception in all men with cancer who present for cryopreservation of semen prior to treatment in whom spermatozoa (even in very low concentrations) are present in the ejaculate.
本研究旨在评估癌症治疗对男性自然生殖及辅助生殖潜能的影响。邀请了一组计划接受放疗和/或化疗的癌症男性患者参与研究。对22份治疗前后的精液样本进行了分析。根据当前可用的一系列生育治疗方案评估了参与者的生殖潜能。治疗前27%的患者精子浓度异常,而治疗后平均20个月,这一比例为68%。59%的患者在接受放疗和/或化疗后精子浓度出现临床上显著下降;23%的患者治疗后出现无精子症。82%的睾丸恶性肿瘤患者治疗后出现少精子症或无精子症。只有一名患者治疗后活动精子百分比出现临床上显著下降。治疗前精液冷冻保存改善了55%患者的生育前景。卵胞浆内单精子注射(ICSI)进一步提高了14%患者的生育前景。在没有冷冻保存精液或精液耗尽后,ICSI可提高45%患者的生育前景。一名无精子症的睾丸癌幸存者在化疗8年后,通过睾丸活检获取的精子经ICSI实现了受精。研究得出结论,化疗和/或放疗可能会使精液浓度降低到导致男性不育的程度。治疗后精子浓度下降的严重程度不可预测,但在睾丸恶性肿瘤患者以及接受放疗或烷化化疗药物治疗的患者中可能最为严重。出于不明原因,并非所有男性都愿意接受治疗后生育潜能的评估。提高患者对癌症及癌症治疗对生殖潜能影响的认识和教育至关重要。随着ICSI的出现,对于所有在治疗前前来冷冻精液且射精中有精子(即使浓度很低)的癌症男性患者,都有可能提供相当合理的受孕机会。